Showing 7,521 - 7,540 results of 18,042 for search 'significantly ((((((linear decrease) OR (nn decrease))) OR (a decrease))) OR (teer decrease))', query time: 0.55s Refine Results
  1. 7521

    DataSheet2_Chitinase 1: a novel therapeutic target in metabolic dysfunction-associated steatohepatitis.docx by Jung Hoon Cha (19723588)

    Published 2024
    “…</p>Conclusions<p>Our study underscores the pivotal role of CHIT1 in MASH. The observed significant improvement in inflammation and hepatic fibrosis, particularly at higher doses of the CHIT1 inhibitor, strongly suggests the potential of CHIT1 as a therapeutic target in MASH accompanied by progressive liver fibrosis.…”
  2. 7522

    DataSheet1_Chitinase 1: a novel therapeutic target in metabolic dysfunction-associated steatohepatitis.zip by Jung Hoon Cha (19723588)

    Published 2024
    “…</p>Conclusions<p>Our study underscores the pivotal role of CHIT1 in MASH. The observed significant improvement in inflammation and hepatic fibrosis, particularly at higher doses of the CHIT1 inhibitor, strongly suggests the potential of CHIT1 as a therapeutic target in MASH accompanied by progressive liver fibrosis.…”
  3. 7523

    The Patient Global Impression of Change as a complementary tool to account for neurobehavioral and mental health symptom improvement for patients with concussion by Rosemay A. Remigio-Baker (7864583)

    Published 2024
    “…</p> <p>Higher PGIC scores were related to a higher prevalence of clinically-relevant <i>decrease</i> in NSI, PCL-5 or PHQ-8 scores. …”
  4. 7524
  5. 7525
  6. 7526

    Crossing Barriers<i>: In Vitro</i> Cancer Model for Studying Monocyte Migration across Endothelial Barriers by Mandeep K. Marway (21734690)

    Published 2025
    “…The endothelial vessel wall plays a significant role in the migration, activation, and polarization of these monocytes. …”
  7. 7527

    Crossing Barriers<i>: In Vitro</i> Cancer Model for Studying Monocyte Migration across Endothelial Barriers by Mandeep K. Marway (21734690)

    Published 2025
    “…The endothelial vessel wall plays a significant role in the migration, activation, and polarization of these monocytes. …”
  8. 7528

    Crossing Barriers<i>: In Vitro</i> Cancer Model for Studying Monocyte Migration across Endothelial Barriers by Mandeep K. Marway (21734690)

    Published 2025
    “…The endothelial vessel wall plays a significant role in the migration, activation, and polarization of these monocytes. …”
  9. 7529
  10. 7530
  11. 7531
  12. 7532
  13. 7533

    Baseline characteristics. by Daniela Sánchez-Santiesteban (21192342)

    Published 2025
    “…Lower income levels are associated with decreased survival, potentially due to delays in diagnosis or treatment and a higher probability of advanced staging at diagnosis, These inequities persist even among relatively advantaged populations, such as formal employee who are assumed to have fewer barriers to accessing healthcare services compared to informal workers.…”
  14. 7534
  15. 7535
  16. 7536

    Table 1_Efficacy and safety of dietary polyphenol supplements for COPD: a systematic review and meta-analysis.docx by Dongsheng Wu (2469307)

    Published 2025
    “…</p>Results<p>The randomized controlled trials (RCTs) included in this review examined dietary supplementation with eight polyphenols—curcumin, resveratrol, anthocyanins, quercetin, salidroside, dietary beetroot juice, pomegranate juice, and adjunctive oral AKL1 treatment—across a total of 894 participants. This systematic review and meta-analysis revealed that, compared to a placebo; ① Curcumin significantly reduced systolic blood pressure (SBP) and improved FEV1(SMD=-0.82, 95%CI -1.53 to -0.11); ② Salidroside was effective in reducing thrombotic markers (TT, D-D), inflammatory factors (TNF-α) and symptom scores (CAT) (p<0.01); ③ Resveratrol significantly downregulates serum TNF-α and IL-8 levels (p=0.003); ④ Anthocyanins may accelerate lung function decline (decreased FEV1/FVC, which needs to be interpreted with caution); ⑤ Other polyphenols (quercetin, pomegranate juice, AKL1, etc.) did not show significant efficacy or insufficient evidence. …”
  17. 7537

    Table 1_The efficacy of infliximab combined with partial enteral nutrition in the treatment of Crohn’s disease: a cohort study.docx by Chen Huang (202847)

    Published 2025
    “…</p>Results<p>Among the 176 included patients, 99 (56%) were in the IFX monotherapy group, and 77 (44%) were in the IFX + PEN group. A significantly higher proportion of patients in the IFX + PEN group achieved clinical response (defined as a CDAI decrease ≥70 points) compared to those in the IFX group at 14 weeks (87.01% vs. 74.75%, p = 0.043), as well as a higher proportion achieving endoscopic remission at 54 weeks (84.42% vs. 65.66%, p = 0.005). …”
  18. 7538
  19. 7539

    Table 4_Outcomes after liposuction-based treatment of lymphedema: a systematic review and meta-analysis.docx by Junzhe Chen (5729912)

    Published 2025
    “…Combined approaches achieved slightly lower reductions (87.31%), but significantly decreased compression dependence, improved lymphatic function, and enhanced QOL. …”
  20. 7540

    Supplementary Material for: Seizure Burden Before and After Lidocaine as Add-on Therapy in (a)EEG-Confirmed Neonatal Seizures by figshare admin karger (2628495)

    Published 2025
    “…After LDC administration, median TSB decreased significantly from 31 (interquartile range, IQR 16–68) to 0 minutes (IQR 0–0, p<0.01), and MSB from 10 (IQR 6–41) to 0 min/hour (IQR 0–0, p<0.01). …”